EDIT
Editas Medicine Inc
Halal Rating :
Last Price
$1.21
Last updated:
Market Cap
-
7D Change
4.31%
1 Year Change
-85.47%
Company Overview
Industries
Exchange
Next Earnings Date
Editas Medicine Inc is a clinical-stage genome editing company focused on developing therapies to treat serious diseases. The company leverages its proprietary CRISPR gene-editing platform to develop transformative medicines. Their pipeline includes treatments for various genetic diseases, with their lead program focusing on treating genetic eye disorders.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $61000.0 | $65.73m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $513000.0 | $72.42m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $1.14m | $68.13m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Editas Medicine Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.